semaglutide and liver disease Active ingredient in weight loss drug Wegovy may help treat type of fatty disease: Study Fatty liver disease quietly raises

doi: 10.1016/j.celrep.2020.108245

Considering Semaglutide for Weight Loss

PadilhaMDanneskiold-SamseNBBrejnrodAHoffmannCCabralVPIaucciJMet alThe human milk microbiota is modulated by maternal diet

Tirzepatide is an approved, extensively studied dual agonist with a proven safety record, commercial availability, and the most comprehensive Phase 3 dataset in the GLP-1 class

However, information about the GLP-1 pulmonary aspiration risk was not included on the warning labels for Ozempic, Wegovy and other widely used drugs in this class, until now

GLP-1 Receptor Agonists: Market Momentum and the Critical Role of Analytics in Development and Bioequivalence 08 May 2026 The science, market drivers and analytical challenges shaping GLP-1 therapies Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly emerged as one of the most transformative classes of therapeutics in modern pharmaceutical development